We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-13.94%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.49B
AUM Growth
-$764M
Cap. Flow
-$255M
Cap. Flow %
-10.24%
Top 10 Hldgs %
45.62%
Holding
96
New
13
Increased
17
Reduced
38
Closed
17
Avg Time Held
1.2 years
Top 10 Avg Time Held
1.2 years
Top 20 Avg Time Held
1.2 years

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$46.6M
2
BMY icon
Bristol-Myers Squibb
BMY
+$45.9M
3
MDT icon
Medtronic
MDT
+$39.2M
4
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$37.5M
5
EPZM
Epizyme, Inc
EPZM
+$33.5M

Top Sells

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$50M
2
BLUE icon
bluebird bio
BLUE
+$36.8M
3
ELV icon
Elevance Health
ELV
+$32.6M
4
CNC icon
Centene
CNC
+$32.1M
5
NUVA
NuVasive, Inc.
NUVA
+$31.2M

Sector Composition

Rank Sector Weight
1 Healthcare 96.57%
2 Miscellaneous 1.72%
3 Financials 1.69%
4 Energy 0.02%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
GRTS icon
26
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$35.1M 1.41%
2,269,136
+26,500
+1% +$506K
2018 Q3
1 quarter
DCPH icon
27
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$34.7M 1.4%
1,653,180
+176,600
+12% +$4.34M
2017 Q3
5 quarters
ELV icon
28
Elevance Health
ELV
$93.3B
$30.3M 1.22%
115,500
-118,500
-51% -$32.6M
2018 Q2
2 quarters
UNH icon
29
UnitedHealth
UNH
$368B
$28.8M 1.16%
115,500
-30,320
-21% -$8.01M
2016 Q3
9 quarters
OXFD
30
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$28.5M 1.14%
2,227,507
-7,900
-0.4% -$120K
2013 Q4
20 quarters
TEVA icon
31
Teva Pharmaceutical Industries Limited
TEVA
$48.3B
$28.2M 1.13%
+1,828,900
New +$37.5M
2018 Q4
0 quarters
CVS icon
32
CVS Health
CVS
$118B
$25.1M 1.01%
382,400
-11,900
-3% -$888K
2018 Q3
1 quarter
VAPO
33
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$24.9M 1%
+155,878
New +$22.5M
2018 Q4
0 quarters
ANAB icon
34
AnaptysBio
ANAB
$1.42B
$23.2M 0.93%
364,050
-266,200
-42% -$19.8M
2017 Q4
4 quarters
CBAY icon
35
DELISTED
Cymabay Therapeutics
CBAY
$23.2M 0.93%
2,948,865
-44,700
-1% -$425K
2017 Q3
5 quarters
MOR icon
36
DELISTED
MorphoSys AG American Depositary Shares
MOR
$22.6M 0.91%
895,600
-4,300
-0.5% -$113K
2018 Q2
2 quarters
REPL icon
37
Replimune Group
REPL
$1.07B
$21.9M 0.88%
2,188,957
-4,000
-0.2% -$54.1K
2018 Q3
1 quarter
ICUI icon
38
ICU Medical
ICUI
$4.16B
$21M 0.84%
91,321
-90,651
-50% -$22.3M
2017 Q1
7 quarters
NITE icon
39
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
$20.7M 0.83%
1,795,846
-285,000
-14% -$3.8M
2017 Q3
5 quarters
CBIO icon
40
Crescent Biopharma
CBIO
$478M
$18.7M 0.75%
19,785
-696
-3% -$838K
2017 Q2
6 quarters
PRAH
41
DELISTED
PRA Health Sciences, Inc.
PRAH
$17.9M 0.72%
194,800
-5,200
-3% -$526K
2018 Q3
1 quarter
PEN icon
42
Penumbra
PEN
$12.6B
$17.8M 0.72%
145,608
-71,521
-33% -$9.58M
2015 Q3
13 quarters
HSKA
43
DELISTED
Heska Corp
HSKA
$17M 0.68%
197,713
-163,963
-45% -$16.1M
2017 Q4
4 quarters
JAZZ icon
44
Jazz Pharmaceuticals
JAZZ
$14B
$16.9M 0.68%
136,680
+135,090
+8,496% +$20M
2018 Q2
2 quarters
SIBN icon
45
SI-BONE Inc
SIBN
$888M
$13.4M 0.54%
+640,900
New +$12.1M
2018 Q4
0 quarters
EIDX
46
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$11.7M 0.47%
853,500
-14,200
-2% -$179K
2018 Q2
2 quarters
TCDA
47
DELISTED
Tricida, Inc. Common Stock
TCDA
$11.6M 0.47%
492,600
-2,400
-0.5% -$69K
2018 Q2
2 quarters
TDOC icon
48
Teladoc Health
TDOC
$1.08B
$9.7M 0.39%
195,600
-139,100
-42% -$8.51M
2017 Q4
4 quarters
LOGC
49
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$9.48M 0.38%
+911,287
New +$11M
2018 Q4
0 quarters
SYRS icon
50
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$9.19M 0.37%
164,954
-660
-0.4% -$50.1K
2016 Q2
10 quarters
1
2
3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2018 Portfolio in Review

As of Q4 2018, Redmile Group held 96 positions worth $2.49B, down 24% from $3.25B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Redmile Group withdrew a net $255M in Q4 2018, closing 17 positions and reducing 38 holdings. Its most notable exit was Wellcare Health Plans, Inc., an estimated $50M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Redmile Group opened a new position in Bristol-Myers Squibb worth $44.4M.

  • Redmile Group's largest Q4 2018 buy was Bristol-Myers Squibb: 854,700 shares worth $44.4M.
  • Redmile Group added most to Clovis Oncology, Inc. in Q4 2018, an estimated $46.6M increase.
  • Redmile Group's biggest Q4 2018 reduction was Elevance Health, cutting an estimated $32.6M.
  • Redmile Group fully exited Wellcare Health Plans, Inc. in Q4 2018, selling an estimated $50M.
  • Redmile Group's ten largest holdings make up 46% of its $2.49B portfolio in Q4 2018.
  • Redmile Group opened 13 new positions and closed 17 in Q4 2018.
  • Redmile Group's portfolio value fell 24% quarter-over-quarter to $2.49B.

Based on Redmile Group's 13F filing for Q4 2018, filed 14 Feb 2019.